Transient receptor potential vanilloid subtype 1 contributes to mesencephalic dopaminergic neuronal survival by inhibiting microglia-originated oxidative stress

Brain Research Bulletin

Volumn 89, Issue 3-4, 2012, Pages 92-96

  Park, Eun S ^a   Kim, Sang R ^b   Jin, Byung K ^a  

^a Kyung Hee University Hospital   (South Korea)

^b Kyungpook National University   (South Korea)

Author keywords

1 Methyl 4 phenylpyridinium (MPP+); Capsaicin; Microglia; Parkinson's disease; ROS; TRPV1

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; CAPSAICIN; CAPSAZEPINE; REACTIVE OXYGEN METABOLITE; TYROSINE 3 MONOOXYGENASE; VANILLOID RECEPTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL CULTURE; CELL SURVIVAL; COCULTURE; DOPAMINERGIC NERVE CELL; FEMALE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MEDIAL FOREBRAIN BUNDLE; MICROGLIA; NERVE CELL NECROSIS; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANALYSIS OF VARIANCE; ANIMALS; ANTIGENS, CD; CAPSAICIN; CELL COUNT; CELLS, CULTURED; COCULTURE TECHNIQUES; CULTURE MEDIA, CONDITIONED; DOPAMINERGIC NEURONS; DRUG INTERACTIONS; FEMALE; FUNCTIONAL LATERALITY; MESENCEPHALON; MICROGLIA; NERVE DEGENERATION; NEUROTOXINS; OXIDATIVE STRESS; PHOSPHOPYRUVATE HYDRATASE; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; SENSORY SYSTEM AGENTS; SUBSTANTIA NIGRA; TRPV CATION CHANNELS; TYROSINE 3-MONOOXYGENASE;

EID: 84866433806     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2012.07.001     Document Type: Article

References (23)

1. Becatti M., Prignano F., Fiorillo C., Pescitelli L., Nassi P., Lotti T., Taddei N. The involvement of Smac/DIABLO, p53, NF-kB, and MAPK pathways in apoptosis of keratinocytes from perilesional vitiligo skin: protective effects of curcumin and capsaicin. Antioxidants and Redox Signalling 2010, 13:1309-1321.
2. Bharath S., Hsu M., Kaur D., Rajagopalan S., Andersen J.K. Glutathione, iron and Parkinson's disease. Biochemical Pharmacology 2002, 64:1037-1048.
3. Block M.L., Zecca L., Hong J.S. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nature Reviews Neuroscience 2007, 8:57-69.
4. Burguillos M.A., Deierborg T., Kavanagh E., Persson A., Hajji N., Garcia-Quintanilla A., Cano J., Brundin P., Englund E., Venero J.L., Joseph B. Caspase signalling controls microglia activation and neurotoxicity. Nature 2011, 472:319-324.
5. Caterina M.J., Julius D. The vanilloid receptor: a molecular gateway to the pain pathway. Annual Review of Neuroscience 2001, 24:487-517.
6. Choi S.H., Joe E.H., Kim S.U., Jin B.K. Thrombin-induced microglial activation produces degeneration of nigral dopaminergic neurons in vivo. Journal of Neuroscience 2003, 23:5877-5886.
7. Choi S.H., Lee D.Y., Chung E.S., Hong Y.B., Kim S.U., Jin B.K. Inhibition of thrombin-induced microglial activation and NADPH oxidase by minocycline protects dopaminergic neurons in the substantia nigra in vivo. Journal of Neurochemistry 2005, 95:1755-1765.
8. Chung E.S., Jin B.K. Disialogangliosides induce neurodegeneration in rat mesencephalic cultures. Biochemical and Biophysical Research Communications 2006, 346:572-577.
9. Chung Y.C., Bok E., Huh S.H., Park J.Y., Yoon S.H., Kim S.R., Kim Y.S., Maeng S., Park S.H., Jin B.K. Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation. Journal of Immunology 2011, 187:6508-6517.
10. Dawson T.M., Dawson V.L. Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003, 302:819-822.
11. Guo S.Y., Yang G.P., Jiang D.J., Wang F., Song T., Tan X.H., Sun Z.Q. Protection of capsaicin against hypoxia-reoxygenation-induced apoptosis of rat hippocampal neurons. Canadian Journal of Physiology and Pharmacology 2008, 86:785-792.
12. Hirsch E.C., Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection. Lancet Neurology 2009, 8:382-397.
13. +) neurotoxicity in rats. Neuroscience Letters 1998, 245:61-64.
14. Kim S.R., Lee D.Y., Chung E.S., Oh U.T., Kim S.U., Jin B.K. Transient receptor potential vanilloid subtype 1 mediates cell death of mesencephalic dopaminergic neurons in vivo and in vitro. Journal of Neuroscience 2005, 25:662-671.
15. Lee D.Y., Park K.W., Jin B.K. Thrombin induces neurodegeneration and microglial activation in the cortex in vivo and in vitro: proteolytic and non-proteolytic actions. Biochemical and Biophysical Research Communications 2006, 346:727-738.
16. Liberatore G.T., Jackson-Lewis V., Vukosavic S., Mandir A.S., Vila M., McAuliffe W.G., Dawson V.L., Dawson T.M., Przedborski S. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nature Medicine 1999, 5:1403-1409.
17. Miller R.L., James-Kracke M., Sun G.Y., Sun A.Y. Oxidative and inflammatory pathways in Parkinson's disease. Neurochemical Research 2009, 34:55-65.
18. +. Neuroreport 2004, 15:1039-1044.
19. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1998, Academic, San Diego, CA.
20. Savitt J.M., Dawson V.L., Dawson T.M. Diagnosis and treatment of Parkinson disease: molecules to medicine. Journal of Clinical Investigation 2006, 116:1744-1754.
21. Shan S., Hong-Min T., Yi F., Jun-Peng G., Yue F., Yan-Hong T., Yun-Ke Y., Wen-Wei L., Xiang-Yu W., Jun M., Guo-Hua W., Ya-Ling H., Hua-Wei L., Ding-Fang C. New evidences for fractalkine/CX3CL1 involved in substantia nigral microglial activation and behavioral changes in a rat model of Parkinson's disease. Neurobiology and Aging 2011, 32:443-458.
22. Singh S., Das T., Ravindran A., Chaturvedi R.K., Shukla Y., Agarwal A.K., Dikshit M. Involvement of nitric oxide in neurodegeneration: a study on the experimental models of Parkinson's disease. Redox Report 2005, 10:103-109.
23. West M.J., Slomianka L., Gundersen H.J. Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anatomical Record 1991, 231:482-497.